Business
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
Board of leading experts in breast cancer to support development of clinical plans SAN JOSE, Calif., Feb. 21, 2023 /PRNewswire/ -- Anixa Biosciences, Inc.
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"Board of leading experts in breast cancer to support development of clinical plans\nSAN JOSE, Calif., Feb. 21, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the formation of its Breast Cancer Clinical Advisory Board comprising preeminent experts across the breast cancer research and clinical development fields. This represents another milestone as the Company prepares for the next steps in advancing its breast cancer vaccine.\n\n \n \n \n \n \n \n\n \n\"We are privileged to have the opportunity to work with leading experts in the breast cancer field who have extensive experience in and understanding of the clinical development of treatments and preventions for breast cancer,\" stated Amit Kumar, Ph.D., Chairman and CEO of Anixa. \"Working with these individuals will better equip Anixa to plan and prepare for future clinical trials of our breast cancer vaccine.\"\nThe Anixa Biosciences Breast Cancer Clinical Advisory Board is comprised of the following members:\nArnold Baskies, MD, FACS, is a specialist in surgical oncology and general surgery, affiliated with Virtua Health Systems. He is former Chairman of the National Board of Directors of the American Cancer Society and current Chair of the society's Global Cancer Control Advisory Council. He is a member of the Global Breast Cancer Initiative, World Health Organization (WHO), and Director and Scientific Advisory Board Member of Anixa Biosciences.\nG. Thomas Budd, MD, FACP, is a specialist in breast cancer and the principal investigator of the Cleveland Clinic and Anixa partnered Phase 1 trial of the Breast Cancer Vaccine. He is Professor of Medicine in the Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Cancer Center, and Professor in the Department of Medicine, School of Medicine and member of the Immune Oncology Program, Case Comprehensive Cancer Center. He is a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).\nLisa H. Butterfield, Ph.D., is a tenured academician (UCLA and University of Pittsburgh) and former President of the Society of Immunotherapy of Cancer (SITC). She is an Adjunct Professor of Microbiology and Immunology at UCSF, a member...